TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD.

Thursday, April 5, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

______________________

1

Public Health Agency of Canada: Chronic Diseases Link here

2

Canadian Institute for Health Information: A Snapshot of Health Care in Canada as demonstrated by Top 10 List. P.6. Available here.

3

Statistics Canada. Leading Cause of Death by Sex.http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth36a-eng.htm

4

N. Mittmann et. Al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Available here.

5

Canadian Lung Association. COPD Signs & Symptoms. Available here. 

6

Soler-Cataluna, JJ, et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925-931.

7

Cote, CG, Dordelly, LJ, Celli, BR (2007) Impact of COPD exacerbations on patient-centered outcomes. Chest, 131(3); 696-704

8

Rennard S, Decramer Et al. Impact of COPD in North America and Europe in 2000: Subjects' perspective of confronting COPD International Survey. European Respiratory Journal. 2002:20 799-805.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store